• Luciana Jesus Bernini, Andrea Name Colado Simão, Daniela Frizon Alfieri, Marcell Alysson Batisti Lozovoy, Naiara Lourenço Mari, Cínthia Hoch Batista de Souza, Isaías Dichi, and Giselle Nobre Costa.
• Program of Master in Dairy Science and Technology, University of North Parana-Unopar, Londrina, Parana, Brazil.
• Nutrition. 2016 Jun 1; 32 (6): 716-9.

ObjectiveHuman studies have shown the beneficial effects of probiotic microorganisms on the parameters of metabolic syndrome (MetS) and other cardiovascular risks, but to our knowledge the effect of Bifidobacterium lactis has not yet been reported. The aim of this study was to evaluate the effect of consumption of milk containing the probiotic B. lactis HN019 on the classical parameters of MetS and other related cardiovascular risk factors.MethodsFifty-one patients with MetS were selected and divided into a control group (n = 25) and a probiotic group (n = 26). The probiotic group consumed fermented milk with probiotics over the course of 45 d. The effects of B. lactis on lipid profile, glucose metabolism, and proinflammatory cytokines (tumor necrosis factor-α and interleukin-6) were assessed in blood samples of the individuals at the baseline and after 45 d.ResultsDaily ingestion of 80 mL fermented milk with 2.72 × 10(10) colony-forming units of B. lactis HN019 showed significant reduction in body mass index (P = 0.017), total cholesterol (P = 0.009), and low-density lipoprotein (P = 0.008) compared with baseline and control group values. Furthermore, a significant decrease in tumor necrosis factor-α (P = 0.033) and interleukin-6 (P = 0.044) proinflammatory cytokines was observed.ConclusionThese data showed potential effects of B. lactis HN019 in reducing obesity, blood lipids, and some inflammatory markers, which may reduce cardiovascular risk in patients with MetS.Copyright © 2016 Elsevier Inc. All rights reserved.

20 keywords...

hide…